Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARA American Renal Associates	$11.52	$11.50	$5.57 ▼ $11.98	$397.94M	1.11	106,940 shs	9,831 shs
ATRC AtriCure	$29.26 -1.6%	$32.50	$20.20 ▼ $43.11	$1.45B	1.56	583,054 shs	294,855 shs
CLDX Celldex Therapeutics	$22.41 -2.4%	$20.79	$14.40 ▼ $47.00	$1.49B	1.13	964,981 shs	880,628 shs
SDGR Schrodinger	$21.45 -0.9%	$21.99	$16.60 ▼ $28.47	$1.57B	1.58	1.13 million shs	960,299 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARA American Renal Associates	0.00%	0.00%	0.00%	0.00%	0.00%
ATRC AtriCure	-2.07%	-7.21%	-8.74%	-7.06%	+18.67%
CLDX Celldex Therapeutics	-0.04%	+1.28%	+14.51%	+25.52%	-40.77%
SDGR Schrodinger	+1.88%	-0.28%	+3.69%	-15.92%	-6.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARA American Renal Associates	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATRC AtriCure	3.1147 of 5 stars	3.5	4.0	0.0	0.0	1.9	2.5	0.6
CLDX Celldex Therapeutics	2.4468 of 5 stars	4.4	1.0	0.0	0.0	3.6	0.0	0.0
SDGR Schrodinger	1.838 of 5 stars	3.4	1.0	0.0	0.0	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARA American Renal Associates	0.00	N/A	N/A	N/A
ATRC AtriCure	3.00	Buy	$50.67	73.16% Upside
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	123.61% Upside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	52.68% Upside

Current Analyst Ratings Breakdown

Latest ARA, SDGR, CLDX, and ATRC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/30/2025	ATRC AtriCure	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$60.00 ➝ $60.00
4/30/2025	ATRC AtriCure	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $58.00
4/30/2025	ATRC AtriCure	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
4/28/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARA American Renal Associates	$822.52M	0.48	$1.69 per share	6.80	$2.59 per share	4.45
ATRC AtriCure	$465.31M	3.11	N/A	N/A	$9.46 per share	3.09
CLDX Celldex Therapeutics	$7.02M	211.91	N/A	N/A	$11.26 per share	1.99
SDGR Schrodinger	$207.54M	7.58	N/A	N/A	$5.78 per share	3.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARA American Renal Associates	-$13.79M	$0.26	N/A	N/A	N/A	-2.04%	-3.56%	-0.24%	N/A
ATRC AtriCure	-$44.70M	-$0.81	N/A	N/A	N/A	-7.95%	-5.68%	-4.34%	7/29/2025 (Estimated)
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)

Latest ARA, SDGR, CLDX, and ATRC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CLDX Celldex Therapeutics	-$0.86	N/A	N/A	N/A	$1.13 million	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
7/29/2025	Q2 2025	ATRC AtriCure	-$0.15	N/A	N/A	N/A	$130.17 million	N/A
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
4/29/2025	Q1 2025	ATRC AtriCure	-$0.25	-$0.14	+$0.11	-$0.14	$122.92 million	$123.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARA American Renal Associates	N/A	N/A	N/A	N/A	N/A
ATRC AtriCure	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARA American Renal Associates	7.54	1.05	1.02
ATRC AtriCure	0.16	4.11	2.88
CLDX Celldex Therapeutics	N/A	21.67	21.67
SDGR Schrodinger	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARA American Renal Associates	78.42%
ATRC AtriCure	99.11%
CLDX Celldex Therapeutics	N/A
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
ARA American Renal Associates	9.50%
ATRC AtriCure	3.50%
CLDX Celldex Therapeutics	4.40%
SDGR Schrodinger	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARA American Renal Associates	4,977	34.54 million	N/A	Optionable
ATRC AtriCure	1,300	49.51 million	47.77 million	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable

ARA, SDGR, CLDX, and ATRC Headlines

Recent News About These Companies

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

July 18 at 10:25 AM | globenewswire.com

Massachusetts Financial Services Co. MA Sells 186,228 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

July 18 at 5:38 AM | marketbeat.com

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

July 17 at 10:30 AM | finance.yahoo.com

Schrodinger (NASDAQ:SDGR) Given New $30.00 Price Target at KeyCorp

July 15 at 4:44 AM | americanbankingnews.com

KeyCorp Has Lowered Expectations for Schrodinger (NASDAQ:SDGR) Stock Price

July 14, 2025 | marketbeat.com

Schrodinger, Inc. (NASDAQ:SDGR) Position Raised by Stephens Investment Management Group LLC

July 13, 2025 | marketbeat.com

BMO Capital Remains a Buy on Schrodinger (SDGR)

July 11, 2025 | theglobeandmail.com

Morgan Stanley Assumes Coverage on Schrödinger (SDGR) Stock

July 10, 2025 | finance.yahoo.com

Allspring Global Investments Holdings LLC Boosts Holdings in Schrodinger, Inc. (NASDAQ:SDGR)

July 7, 2025 | marketbeat.com

SDGR - Schrodinger Inc Ordinary Shares Financials - Morningstar

July 5, 2025 | morningstar.comM

MS initiates coverage on AI Biotechs, flags key pipeline catalysts

July 3, 2025 | investing.com

Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505

July 3, 2025 | msn.com

Morgan Stanley Initiates Coverage on Schrodinger (NASDAQ:SDGR)

July 3, 2025 | marketbeat.com

Schrödinger, Inc. (SDGR) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

July 2, 2025 | prnewswire.com

Short SDGR: Schrödinger bounces from 2024 midpoint, trading range low as potential short-term target

July 1, 2025 | invezz.comI

Sumitomo Mitsui Trust Group Inc. Sells 48,103 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

July 1, 2025 | marketbeat.com

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

June 27, 2025 | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 23, 2025 | globenewswire.com

17,493 Shares in Schrodinger, Inc. (NASDAQ:SDGR) Bought by Palumbo Wealth Management LLC

June 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
JPMorgan Chase: The Financial Fortress Built for Today's Investor
By Jeffrey Neal Johnson | June 23, 2025
View JPMorgan Chase: The Financial Fortress Built for Today's Investor

ARA, SDGR, CLDX, and ATRC Company Descriptions

American Renal Associates NYSE:ARA

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

AtriCure NASDAQ:ATRC

$29.26 -0.49 (-1.65%)

Closing price 04:00 PM Eastern

Extended Trading

$29.26 +0.00 (+0.02%)

As of 04:10 PM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Celldex Therapeutics NASDAQ:CLDX

$22.41 -0.56 (-2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$22.75 +0.34 (+1.52%)

As of 04:31 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Schrodinger NASDAQ:SDGR

$21.45 -0.20 (-0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$21.60 +0.15 (+0.70%)

As of 04:35 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time